Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports. (December 2017)

• Record Type: Journal Article
• Authors: Chen, Guoyong; Sun, Janjun; Wei, Sidong; Chen, Yongfeng; Tang, Gaofeng; Xie, Zhantao; Xu, Huaen; Chen, Janbin; Zhao, Huibo; Yuan, Zhenhua; Wang, Weiwei; Liu, Guangbo; Wang, Bing; Niu, Biao
• Is Part Of: Journal of international medical research. Volume 45:Number 6(2017)
• Page Start: 2146
• Page End: 2152
• Publication Date: 2017-12
• Subjects: ABO-incompatible transplantation -- living-donor transplantation -- liver transplantation -- splenectomy -- treatment; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060517710407
• Languages: English
• ISSNs: 0300-0605

Abstract

ABO-incompatible (ABO-i) living-donor liver transplantation (LDLT) is performed if an ABO-compatible graft cannot be obtained. However, a perfect desensitization protocol has not been established worldwide, especially for simultaneous ABO-i LDLT and splenectomy. We herein report two cases of ABO-i LDLT. To the best of our knowledge, this is the first case report of ABO-i LDLT in an adult patient in China. Splenectomy and T-cell-targeted immunosuppression (basiliximab) was used to overcome the blood group barrier in these recipients. The patients had good graft function without signs of antibody-mediated rejection throughout the 12-month follow-up. Thus, ABO-i LDLT with splenectomy is undoubtedly life-saving when an ABO-compatible graft cannot be obtained for patients in critical condition.